Text Size
209 studies found for:    "PDGFRA-associated chronic eosinophilic leukemia" OR "Hypereosinophilic Syndrome"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Unknown † Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia (CEL);   Myeloproliferative Disorders
Intervention: Drug: STI571
2 Completed Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia;   Chronic Idiopathic Hypereosinophilia
Intervention: Drug: Imatinib
3 Terminated A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: imatinib mesylate
4 Recruiting Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Imatinib Mesylate
5 Recruiting Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)
Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
6 Completed Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: SCH55700
7 Recruiting Steroid Treatment for Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Corticosteroids
8 Completed Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
9 Completed Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Conditions: Hypereosinophilia;   Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
10 Recruiting Identification of New Markers in the Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Biological: biologie sample
11 Withdrawn Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Conditions: Eosinophilia;   Hypereosinophilic Syndrome
Intervention: Drug: Gleevec
12 Completed Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Conditions: Hypereosinophilic Syndromes;   Eosinophilic Gastroenteritis;   Churg-Strauss Syndrome;   Eosinophilic Esophagitis
Intervention: Drug: Mepolizumab
13 Active, not recruiting Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
14 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
15 Active, not recruiting A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers.
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive);   Hypereosinophilic Syndrome;   Systemic Mastocytosis
Intervention: Drug: Nilotinib
16 Completed Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: vorinostat;   Drug: cytarabine;   Drug: etoposide;   Other: pharmacological study;   Other: laboratory biomarker analysis
17 Completed Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Conditions: Hypereosinophilic Syndrome;   Systemic Mastocytosis;   Chronic Myelomonocytic Leukemia;   Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
18 Terminated Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: idarubicin;   Drug: cytarabine;   Biological: bevacizumab;   Other: laboratory biomarker analysis
19 Completed Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: valspodar;   Biological: filgrastim;   Drug: busulfan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Biological: aldesleukin;   Other: clinical observation;   Other: pharmacological study
20 Completed 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Condition: Leukemia
Interventions: Drug: 2-CdA;   Drug: Ara-C;   Drug: G-CSF (Granulocyte colony-stimulating factor)
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years